FDA reverses course, won't approve leucovorin for autism
The Brown University Psychopharmacology Update · 2026-05 · 37 (5) · 5-5
DOI: 10.1002/pu.31442 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 08.04.2026.
Abstract (Originalsprache)
The Trump administration has changed direction from its prior intent to approve an indication for the folic acid derivative leucovorin that had raised serious concern in the research and legal communities (see April 2026 issue of the Update). The Food and Drug Administration (FDA) announced in March that it will not approve leucovorin for the treatment of some patients with autism. The FDA had announced at a September 2025 press conference that it intended to approve leucovorin, marketed as Wellcovorin, in autism treatment despite no evidence of benefit from any randomized controlled trial. Critics of the announcement pointed out that the FDA appeared to be basing its decision-making solely on evidence from case reports and mechanistic data — a much lower standard than the randomized trial evidence customarily required for drug approvals. Now the FDA says its scientific review has determined that there is not enough evidence to support the use of leucovorin to treat patients with autism. The agency is approving a new indication for the drug in treating cerebral folate deficiency in patients with a rare variant in the folate receptor 1 gene. In announcing this new indication, the FDA stated that the approval was based on a systematic review of published case reports and mechanistic data, with no data from clinical trials cited.
Zitieren
APA
(2026). FDA reverses course, won't approve leucovorin for autism. The Brown University Psychopharmacology Update, 37(5), 5-5. https://doi.org/10.1002/pu.31442
Vancouver
FDA reverses course, won't approve leucovorin for autism. The Brown University Psychopharmacology Update. 2026;37(5):5-5. doi:10.1002/pu.31442
BibTeX
@article{euvimed2026,
title = {FDA reverses course, won't approve leucovorin for autism},
journal = {The Brown University Psychopharmacology Update},
year = {2026},
volume = {37},
number = {5},
pages = {5--5},
doi = {10.1002/pu.31442}
}
EUVIMED